Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Olaparib in Recurrent/Metastatic Nasopharyngeal Cancer
NCT04825990Phase 2Active, not recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Mar 2022
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in nasopharyngeal carcinoma (NPC), sponsored by Gruppo Oncologico Nord Ovest. Started Mar 2022; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04825990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825990.